share_log

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3:募資說明書
美股sec公告 ·  05/23 04:11
牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC (BDRX.US) announced the successful exercise of previously issued warrants, resulting in approximately $7 million in gross proceeds. The funds will primarily cover the first year of the eRapa Phase 3 trial in Familial Adenomatous Polyposis (FAP), unlocking additional non-dilutive grant funding. The exercised warrants, initially priced at $2.20, were exercised at a reduced price of $1.50 per American Depositary Share (ADS). The ADSs are registered under an effective SEC registration statement (File No. 333-274895). In exchange for the cash exercise of the warrants, the holders received new unregistered Replacement Warrants to purchase additional ADSs. The Replacement Warrants have an exercise price of $2.50 per ADS and terms of one and five years. The net proceeds from the offering will be used...Show More
Biodexa Pharmaceuticals PLC (BDRX.US) announced the successful exercise of previously issued warrants, resulting in approximately $7 million in gross proceeds. The funds will primarily cover the first year of the eRapa Phase 3 trial in Familial Adenomatous Polyposis (FAP), unlocking additional non-dilutive grant funding. The exercised warrants, initially priced at $2.20, were exercised at a reduced price of $1.50 per American Depositary Share (ADS). The ADSs are registered under an effective SEC registration statement (File No. 333-274895). In exchange for the cash exercise of the warrants, the holders received new unregistered Replacement Warrants to purchase additional ADSs. The Replacement Warrants have an exercise price of $2.50 per ADS and terms of one and five years. The net proceeds from the offering will be used to advance clinical stage assets and for general corporate purposes. The Replacement Warrants and the ADSs issuable upon their exercise have not been registered under the Securities Act of 1933 and were offered only to accredited investors. Biodexa has committed to filing a registration statement with the SEC for the resale of the ADSs issuable upon exercise of the Replacement Warrants.
Biodexa Pharmicals PLC(BDRX.US)宣佈成功行使先前發行的認股權證,總收益約爲700萬美元。這些資金將主要用於家族性腺瘤性息肉病(FAP)eRapa 3期試驗的第一年,從而解鎖額外的非稀釋性撥款。行使的認股權證最初定價爲2.20美元,以每股美國存托股票(ADS)1.50美元的降價行使。ADS是根據有效的美國證券交易委員會註冊聲明(文件編號333-274895)註冊的。作爲兌現認股權證的交換,持有人獲得了新的未註冊替代認股權證,用於購買額外的ADS。替代認股權證的行使價爲每份ADS2.50美元,期限爲一年和五年。此次發行的淨收益將用於推進臨床階段的資產和一般公司用途。替代認股權證和行使後可發行的美國存託憑證尚未根據1933年《證券法》註冊,僅向合格投資者發行。Biodexa已承諾向美國證券交易委員會提交註冊聲明,以轉售行使替代認股權證後可發行的美國存託憑證。
Biodexa Pharmicals PLC(BDRX.US)宣佈成功行使先前發行的認股權證,總收益約爲700萬美元。這些資金將主要用於家族性腺瘤性息肉病(FAP)eRapa 3期試驗的第一年,從而解鎖額外的非稀釋性撥款。行使的認股權證最初定價爲2.20美元,以每股美國存托股票(ADS)1.50美元的降價行使。ADS是根據有效的美國證券交易委員會註冊聲明(文件編號333-274895)註冊的。作爲兌現認股權證的交換,持有人獲得了新的未註冊替代認股權證,用於購買額外的ADS。替代認股權證的行使價爲每份ADS2.50美元,期限爲一年和五年。此次發行的淨收益將用於推進臨床階段的資產和一般公司用途。替代認股權證和行使後可發行的美國存託憑證尚未根據1933年《證券法》註冊,僅向合格投資者發行。Biodexa已承諾向美國證券交易委員會提交註冊聲明,以轉售行使替代認股權證後可發行的美國存託憑證。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。